NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-248-2016-0-CH-07 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer CH EP 15868296.3 Issued
NCI E-248-2016-0-EP-03 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer EP National Stage 15868296.3 Issued
NCI E-248-2016-0-IE-11 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer IE EP 15868296.3 Issued
NCI E-248-2016-0-FR-09 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer FR EP 15868296.3 Issued
NCI E-248-2016-0-DE-08 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer DE EP 15868296.3 Issued
NCI E-248-2016-0-PCT-02 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer PCT PCT PCT/US2015/064792 Expired
NCI E-203-2004-0-US-04 Replication-Competent Adenoviral Vectors US DIV 14/963,172 9732359 Issued PDF
NCI E-257-2009-1-NZ-12 Use Of IL-15 To Increase Thymic Output and to Treat Lymphopenia NZ DIV 714757 Issued
NIBIB E-314-2013-0-US-04 Octapod Iron Oxide Nanoparticles As High-Performance T2 Contrast Agents For Magnetic Resonance Imaging US National Stage 14/895,745 9974868 Issued PDF
NCI E-312-2005-0-US-06 Peptides and Methods of Use for Treating and Preventing Cancer US CON 14/958,114 Abandoned
NICHD E-234-2008-1-AU-06 Method For Predicting And Detecting Tumor Metastasis AU DIV 2015264870 Abandoned
NCI E-034-2013-0-US-04 MONOMERIC GRIFFITHSIN TANDEMERS US National Stage 14/895,349 9982025 Issued PDF
NCATS E-050-2012-0-HK-09 Cyclodextrin For The Treatment Of Lysosomal Storage Diseases HK EP 15111861.6 Pending
NCI E-239-2010-0-AU-08 Manipulation of Stem Cell Function By P53 Isoforms AU DIV 2015264813 Abandoned
NHLBI E-048-2009-0-US-04 Tensioning Device and Methods for Use US DIV 14/956,238 10285813 Issued PDF
NCI E-162-2009-0-US-10 Pharmaceutical Compositions Which Inhibit FKBP52-Mediated Regulation Of Androgen Receptor Function and Methods of Using Same US DIV 14/955,505 9782399 Issued PDF
NCI E-285-2006-2-US-08 Differential Gene Expression In Physiological and Pathological Angiogenesis US DIV 14/954,509 Abandoned
NIBIB E-314-2013-0-IE-09 Octapod Iron Oxide Nanoparticles As High-Performance T2 Contrast Agents For Magnetic Resonance Imaging IE EP 13886302.2 Issued
NIBIB E-314-2013-0-FR-07 Octapod Iron Oxide Nanoparticles As High-Performance T2 Contrast Agents For Magnetic Resonance Imaging FR EP 13886302.2 Issued
NIBIB E-314-2013-0-DE-06 Octapod Iron Oxide Nanoparticles As High-Performance T2 Contrast Agents For Magnetic Resonance Imaging DE EP 13886302.2 Issued
NIBIB E-314-2013-0-CH-05 Octapod Iron Oxide Nanoparticles As High-Performance T2 Contrast Agents For Magnetic Resonance Imaging CH EP 13886302.2 Issued
NIBIB E-314-2013-0-GB-08 Octapod Iron Oxide Nanoparticles As High-Performance T2 Contrast Agents For Magnetic Resonance Imaging GB EP 13886302.2 Issued
NIA E-101-2010-0-US-04 Regulatory B Cells (tBregs) And Their Uses US CON 14/952,768 9657269 Issued PDF
NHLBI E-175-2012-0-HK-07 Method of Preparing Silca-Coated Nanodiamonds HK National Stage 15111586.0 Pending
NCI E-028-2015-1-KR-08 Anti-Mutated Kras T Cell Receptors KR National Stage 2017-7017289 Issued
NCI E-028-2015-1-SG-12 Anti-Mutated Kras T Cell Receptors SG National Stage 11201704155U Issued
NCI E-028-2015-1-IL-06 Anti-Mutated Kras T Cell Receptors IL National Stage 252258 Issued
NCI E-028-2015-1-CN-04 Anti-Mutated Kras T Cell Receptors CN National Stage 201580070673.7 Issued
NCI E-028-2015-1-MX-09 Anti-Mutated Kras T Cell Receptors MX National Stage MX/a/2017/006865 Issued
NCI E-028-2015-1-JP-07 Anti-Mutated Kras T Cell Receptors JP National Stage 2017-527874 Issued
NCI E-028-2015-1-SA-11 Anti-Mutated Kras T Cell Receptors SA National Stage 517381608 Issued
NCI E-028-2015-1-AU-02 Anti-Mutated Kras T Cell Receptors AU National Stage 2015353720 Issued
NCI E-028-2015-1-AT-17 Anti-Mutated Kras T Cell Receptors AT EP 15807756.0 Issued
NCI E-028-2015-1-BE-18 Anti-Mutated Kras T Cell Receptors BE EP 15807756.0 Issued
NCI E-028-2015-1-NL-28 Anti-Mutated Kras T Cell Receptors NL EP 15807756.0 Issued
NCI E-028-2015-1-GB-24 Anti-Mutated Kras T Cell Receptors GB EP 15807756.0 Issued
NCI E-028-2015-1-CH-19 Anti-Mutated Kras T Cell Receptors CH EP 15807756.0 Issued
NCI E-028-2015-1-TR-35 Anti-Mutated Kras T Cell Receptors TR EP 15807756.0 Issued
NCI E-028-2015-1-CZ-20 Anti-Mutated Kras T Cell Receptors CZ EP 15807756.0 Issued
NCI E-028-2015-1-PT-31 Anti-Mutated Kras T Cell Receptors PT EP 15807756.0 Issued
NCI E-028-2015-1-SE-32 Anti-Mutated Kras T Cell Receptors SE EP 15807756.0 Issued
NCI E-028-2015-1-SK-34 Anti-Mutated Kras T Cell Receptors SK EP 15807756.0 Issued
NCI E-028-2015-1-PL-30 Anti-Mutated Kras T Cell Receptors PL EP 15807756.0 Issued
NCI E-028-2015-1-NO-29 Anti-Mutated Kras T Cell Receptors NO EP 15807756.0 Issued
NCI E-028-2015-1-SI-33 Anti-Mutated Kras T Cell Receptors SI EP 15807756.0 Issued
NCI E-028-2015-1-ES-22 Anti-Mutated Kras T Cell Receptors ES EP 15807756.0 Issued
NCI E-028-2015-1-IE-26 Anti-Mutated Kras T Cell Receptors IE EP 15807756.0 Issued
NCI E-028-2015-1-GR-25 Anti-Mutated Kras T Cell Receptors GR EP 15807756.0 Issued
NCI E-028-2015-1-IT-27 Anti-Mutated Kras T Cell Receptors IT EP 15807756.0 Issued
NCI E-028-2015-1-DE-21 Anti-Mutated Kras T Cell Receptors DE EP 15807756.0 Issued